People · Operator
Named in public records as an officer, director or promoter · active 2011–2016 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Acer Therapeutics Inc. | — | Biotechnology | Series B | $52.2M | $21.2M | 2016 |
| Zelos Therapeutics Inc | — | Pharmaceuticals | Series A | $17.8M | $75.0M | 2011 |
Cynthia Lavoie at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Cynthia Lavoie on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Joseph Zakrzewski | 1 | 6 |
| John Dunn | 1 | 6 |
| Colin Goddard | 1 | 5 |
| Farah Champsi | 1 | 5 |
| Brian MacDonald | 1 | 4 |
| David Hung | 1 | 3 |
| Jaisim Shah | 1 | 3 |
| David Krause | 1 | 3 |
| Donald Hayden | 1 | 3 |
| Jeff Courtney | 1 | 3 |
| Alex Barkas | 1 | 3 |
| Michael S. Richman | 1 | 2 |
| Harry S. Palmin | 1 | 2 |
| David E. Jorden | 1 | 2 |
| Gail J. Maderis | 1 | 2 |
| David B. McWilliams | 1 | 2 |
| Neil K. Warma | 1 | 2 |
| Chris Schelling | 1 | 2 |
| Luc Marengere | 1 | 2 |
| Stephen Aselage | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.